India to United States: Oxaliplatin Export Trade Route
India has recorded 58 verified shipments of Oxaliplatin exported to United States, representing a combined trade value of $4.0M USD. This corridor is served by 11 active Indian exporters, with an average shipment value of $68.1K USD. The leading Indian exporter is GLAND PHARMA LIMITED, which accounts for 55% of total export value with 20 shipments worth $2.2M USD. On the buying side, MEITHEAL PHARMACEUTICALS is the largest importer in United States with $912.7K USD in purchases. The top 3 suppliers — GLAND PHARMA LIMITED, MYLAN LABORATORIES LIMITED, ZYDUS HOSPIRA ONCOLOGY PRIVATE LIMITED — together control of total trade value on this route. All data sourced from Indian Customs (DGFT) shipping bill records. Values reported in FOB USD.
Route Intelligence Overview
The India to United States Oxaliplatin corridor is one of India's established pharmaceutical export routes, with 58 shipments documented worth a combined $4.0M USD. The route is dominated by GLAND PHARMA LIMITED, which alone accounts for roughly 55% of all export value, reflecting the consolidated nature of India's oxaliplatin manufacturing sector.
Across 11 active suppliers, the average shipment value stands at $68.1K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Freight is split between sea (68%) and air (17%), suggesting a mix of scheduled bulk orders and time-sensitive consignments.
Shipment activity peaks during July–September, with an average transit time of 30 days port-to-port. The route has recorded an annual growth rate of 26.6%, placing it at rank #1 among India's top oxaliplatin export destinations globally.
On the import side, key buyers of Indian oxaliplatin in United States include MEITHEAL PHARMACEUTICALS, MYLAN INSTITUTIONAL INC., Fosun Pharma USA Inc and 20 others. MEITHEAL PHARMACEUTICALS is the single largest importer with 7 shipments valued at $912.7K USD.
